The FDA must continue to pressure Chinese authorities to test what is on the market and remove any substandard products found.

Here is another good news/bad news column about the 112th Congress.

Many aid groups who purchase generic drugs for developing countries do not require evidence of bioequivalence.

The design challenge for school choice is to match supply with demand.

The 1984 Hatch-Waxman Act created a streamlined path for generic drugs to reach the market after pioneer drug patents expire. The result has been the most vigorous and competitive generic drug market in the world, but the Hatch-Waxman Act does not apply to most biologics. Isolated from a variety of...

Nobody has asked what financial and scientific burdens new legislation will place on the Food and Drug Administration.

Until government price controls are lifted, the makers of generics will be unable to cover their production costs.